Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
Ertugliflozin L-PGA eqv to Ertugliflozin
MSD PHARMA (SINGAPORE) PTE. LTD.
A10BK04
TABLET, FILM COATED
Ertugliflozin L-PGA eqv to Ertugliflozin 15mg
ORAL
Prescription Only
Pfizer Manufacturing Deutschland GmbH
ACTIVE
2020-03-11
CCDS-MK8835-T-032018 STEGLATRO® Film-coated Tablets 5 mg STEGLATRO® Film-coated Tablets 15 mg 1. INDICATIONS AND USAGE STEGLATRO (ertugliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see 10. CLINICAL STUDIES] . 2. DOSAGE AND ADMINISTRATION 2.1 General The recommended starting dose of STEGLATRO is 5 mg once daily, taken in the morning, with or without food. In patients tolerating STEGLATRO 5 mg once daily, the dose may be increased to 15 mg once daily if additional glycemic control is needed. In patients with volume depletion, correcting this condition prior to initiation of STEGLATRO is recommended [see 5. WARNINGS AND PRECAUTIONS (5.1)] . 2.2 Renal Impairment Assessment of renal function is recommended prior to initiation of STEGLATRO and periodically thereafter [see 5. WARNINGS AND PRECAUTIONS (5.3)] . STEGLATRO should not be initiated in patients with an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m 2 [see 5. WARNINGS AND PRECAUTIONS (5.3) and 7. USE IN SPECIFIC POPULATIONS (7.5)] . Use of STEGLATRO should be discontinued in patients with an eGFR persistently between 45 to <60 mL/min/1.73 m 2 or if eGFR falls below 45 mL/min/1.73 m 2 . 3. INSTRUCTIONS FOR USE Not applicable. 4. CONTRAINDICATIONS History of a serious hypersensitivity reaction to STEGLATRO. 5. WARNINGS AND PRECAUTIONS General STEGLATRO is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. 5.1 Hypotension STEGLATRO causes an osmotic diuresis, which may lead to intravascular volume contraction. Therefore, symptomatic hypotension may occur after initiating STEGLATRO [see 8. ADVERSE REACTIONS (8.1)] , particularly in patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients (≥ 65 years), or patients on diuretics. Before initiating STEGLATRO, volume status should be assessed and corrected if indicated. Monitor for signs and symptoms after initiating therapy Read the complete document